cyrilzakka/clinical-trials huggingface dataset:
Obesity Phenotypes and Its Relation to Cardiovascular Diseases

To determine the association between obesity phenotypes with cardiovascular diseases.

* Primary Outcomes:

  1- To examine the association between different obesity phenotypes and cardiovascular diseases.by using echocardiography, lipid profile
* Secondary Outcomes:

  1. frequency of obesity phenotypes on our locality
  2. Correlation between each type of obesity phenotypes and other metabolic disturbances (e.g. DM, dyslipidemia, NASH)
  3. Correlation between epcardial fat, carotid intimal thickness and different obesity phenotypes.

Obesity is a condition caused by increasing the fat components of body resulting in body weight increase. Obesity leads to several complications like type 2 diabetes, hypertension and cardiovascular events, sleep apnea. But obesity can no longer be evaluated solely by the body mass index (expressed in kg/m2) because it represents a heterogeneous entity (1). As there are several cardio-metabolic imaging studies have shown that some individuals who have a normal weight or who are overweight are at high risk if they have an excess of visceral adipose tissue-a condition often accompanied by accumulation of fat in normally lean tissues (ectopic fat deposition in liver, heart, skeletal muscle, etc.) (2) On the other hand, individuals who are overweight or obese can nevertheless be at much lower risk than expected when faced with excess energy intake if they have the ability to expand their subcutaneous adipose tissue mass, particularly in the gluteal-femoral area, as preferential fat storage in the lower body depot may act as a metabolic buffer and protect other tissues from lipotoxicity caused by lipid overflow and ectopic fat (3). Hence, excessive amounts of visceral adipose tissue and of ectopic fat largely define the cardiovascular disease risk of overweight and moderate obesity (4). Epicardial fat is considered as indicator of cardiovascular risk. Several studies have tested the association between epicardial fat thickness (EFT) and coronary artery disease many studies stated that epicardial fat is independently and linearly associated with CAD and its severity .In this study we aim to monitor the extent of obesity phenotypes association to cardiovascular diseases in patients attending to Obesity Clinic in Assuit Hospital University.

Eligibility Criteria:
Inclusion Criteria:

- Adult patient of 18 years old and above

Exclusion Criteria:

* 1- Patients below 18 years old age (pediatrics and Child).

  2- Pregnant females.

  3- Patients with congenital heart diseases.

  4- Patients with previous bariatric surgery.

  5-Patients with type 1 DM.

  6-Patients with hereditary hyperlipidemia

  .Secondary causes of obesity

include these:Endocrine DisordersCushing SyndromeHypothyroidismPseudohypoparathyroidismType 2 diabetes

Genetic SyndromesPrader-Willi syndromeBardet-Biedel syndromeCohen syndromeCentral Nervous System DisordersHypothalamic TumorTrauma to or inflammation of the hypothalamic regionOtherDrug induced - atypical anti-psychotics, tricyclic antidepressantsBinge eating disorderBulimia nervosa
RSA Study of Furlong Evolution With and Without Collar

The aim of this study is to further investigate the clinical and radiological importance of design changes in cementless hip prosthesis. The investigators have earlier evaluated the classical Furlong HAC total hip prosthesis and a first design change Furlong Active. Now a further development, Furlong Evolution, is to be evaluated. This prosthesis, furthermore, comes with and without a collar, and the investigators are going to randomize between the two. The investigators hypothesize that the new design will be easier to implant and will present equal or less migration than the older designs which would imply a favourable outcome in the long term. The investigators further hypothesize that the collar play no major part for the long term migration and bone remodelling.

We will now do a 10 year follow up of the patients including RSA, DXA and PROMS


Eligibility Criteria:
Inclusion Criteria:

* Primary osteoarthritis of the hip necessitating primary hip replacement
* A femur considered suitable for uncemented fixation of the stem
* Biological age \<75 years old at the inclusion time of the study.

Exclusion Criteria:

* Rheumatoid arthritis
* Malignant disease
* Severe osteoporosis
* Earlier fracture or operation in the hip to be operated on
* Peroperative fracture
* Ongoing corticosteroid (oral) or immunosuppressive medication
* Personal disorders (dementia, alcohol or drug abuse etc) suspected of making completion of the trial uncertain.
Evaluation of the Clinical and Biological Consequences of Levothyrox® Formula Modification

The purpose of this study is to determine whether the recent excipient modification of Levothyrox® in France for a bioequivalent formula has clinical and biological consequence for the patients. The investigators also plan to describe the patient journey in terms of levothyroxine based drugs since this formula modification of Levothyrox®.

Levothyrox® is a levothyroxine based drug marketed in France in order to substitute a lack of thyroid hormones. Because of a lack of stability during time and because of wide inter-batch variability in terms of active molecule, the National Agency of Safety of Medicaments (ANSM) ask to the market authorization holder to develop a new formula without lactose. This new formula, which has been proven to be bioequivalent has been marketed since march 2017 in France. Some patients were predicted to have their thyroid function imbalance because of this modification. The purpose of the study is to analyse, on the patients treated by Levothyroxine® in how many patients this modification has clinical and biological consequences.

Eligibility Criteria:
Inclusion Criteria:

* Thyroid disorder treated by Levothyroxine
* Age over 18 year old
* TSH plasma level within the 12 months before formulation modification
* TSH plasma level within the 6 months after formulation modification

Exclusion Criteria:

- Thyroid dysfunction (hypo or hyperthyroidism) despite Levothyroxine treatment, ie TSH plasma level out of normal range within the 6 months before formula modification
Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt

The main objective of this study is to evaluate decision-making using the Iowa Gambling Task (IGT) among patients with euthymic bipolar disorder according to their personal history of suicide attempt ("suicidal" vs. "not suicidal ").

The secondary objectives of this study are:

A. Evaluate other aspects of cognitive functioning (using the Tower of London, the Probabilistic Reversal-learning task, the Rey Complex Figure, the Reading the Mind in the Eyes test) in euthymic patients with bipolar disorder, depending on the presence or absence of a history of suicide attempt; B. Explore performance on neuropsychological tests depending on the type of therapy administered (lithium salts or valproate monotherapy or in combination with other mood stabilizers); C. Explore a possible relationship between circulating levels of lithium or sodium divalproex results and different neuropsychological tests; D. Establishment of a biobank for this population with leftover blood samples following serum lithium or divalproex testing.

Eligibility Criteria:
Inclusion Criteria:

* The patient was correctly informed about the study
* The patient must be insured or beneficiary of a health insurance plan
* The diagnosis of bipolar disorder is confirmed by the doctor referring the patient to the BEC and confirmed during the preliminary interview at the BEC
* The patient is euthymic on the day of inclusion. This is supported by a short psychiatric interview conducted at the BEC and the completion of the depression and mania scales (score \<= 7 on the HDRS questionnaire and score \<= 7 on the YMRS questionnaire).
* The patient is prescribed a mood stabilizer based on lithium or divalproex.

Exclusion Criteria:

* The patient is under judicial protection, under tutorship or curatorship
* The patient formalizes his/her opposition to the studyd
* It is impossible to correctly inform the patient
* The patient has mental retardation
* The patient has practiced substance abuse or dependence within the 6 months prior to study inclusion (alcool, cannabis, opiates, psychostimulants)
* The patient does not meet euthymic criteria (score \<= 7 on the HDRS questionnaire and score \<= 7 on the YMRS questionnaire).

Uninclusion Criteria:

* The patients withdraws consent during the study
* The patient does not understand directions necessary for the neurpsychological tasks
* The patient is not able to use a computer to complete the neuropsychological tasks
Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.

This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits. The first phase of the research study seeks to evaluate the experience of the first version of the mobile health app within a group of participants and what they think of it.

The investigators are interested in how individuals react to the use of a developed mobile health app and what they think of it.

Eligibility Criteria:
Inclusion Criteria:

Phase 1

* All recruited participants must have owned a smartphone for \>1 year
* English-speaking.
* Patients with prostate cancer aged between 40-75 years will be considered.
* No specific timeframe after prostate cancer diagnosis will be required for these patients.
* No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease).
* Patients may or may not be currently receiving treatment Staff members will be recruited from
* Dana-Farber Cancer Institute Department of Medical Oncology,
* Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75 years old will be considered. Phase 2
* Men diagnosed with prostate cancer presenting to DF/BWHCC
* About to initiate ADT for the first time will be considered.
* Age range 40-75-years
* The ability to walk 400 m
* Medical clearance from their primary physician
* English speaking
* Cognitively alert
* Literate
* Ability to read or hear with or without contacts/glass and hearing aid
* Ownership of a smartphone for \>1yr

Exclusion Criteria:

* Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered
* Post-ADT treatment
* Planned systemic chemotherapy
* Planned treatment with abiraterone or enzalutamide
* Bone metastases
* Acute illness
* Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising
* Subordinates to the PI
Foley Catheter vs Double-balloon Catheter

The efficiency of double-balloon and Foley catheters in the second trimester medical termination of pregnancies will be compared.

Women will be randomised into two groups. Foley catheter was applied to one group and double balloon catheter to the other group. After catheter expulsion or if the catheters did not spontaneously expulsed after 24 hours, i.v. oxytocin infusion will be started. Abortions will be considered successful if there will be no need of another method for abortion.

Eligibility Criteria:
Inclusion Criteria:

* pregnancy termination, gestational age from 14-24 weeks

Exclusion Criteria:

* multiple gestation
HPA Antibodies and the Distribution of Antigen and Antibodies

By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA antigen and antibodies, effect of matching platelet transfusion, all of which in favor of draw a conclusion that it is very important to carry out HPA antibody detection and matching transfusion in early phase.

1. The investigators will detect platelet antibodies of participants who are according with the inclusive criteria.
2. For participants with platelet antibodies, the investigators should screen out cases owning HPA antibodies and further to identify their genotype.
3. Platelet infusion of same type will be applied to half of participants with HPA antibodies as experimental group, and the another half of participants with hematopathy will be infused ordinary platelets as control. The investigators will estimate the effect of matching transfusion through laboratory examination such as platelet count 1 hour and 24 hours after transfusion and clinical feature comparing to control group.
4. Finally, the investigators will obtain several conclusions includes positive frequency of HPA antibodies, the distribution of HPA antigen and antibodies, effect of matching platelet transfusion by analyzing a bunch of relevant information. So, strong evidence will be provide to decide if it is very important to carry out HPA antibody detection and matching transfusion in early phase.

Eligibility Criteria:
Inclusion Criteria:

1. Blood disease patients with voluntary participation in creating records, no gender limitation, 0-99 years of age, first diagnosed or be hospitalized in our hospital with platelet transfusion more than once.
2. Patients transfers from other hospitals which can be confirm the time (\>1) of platelet transfusion.
3. Patient be cured, discharged or dead with the time of platelet transfusion is between 1 to 10 should be included.
4. Patient with HPA antibodies at admission could be considered to be included into same type transfusion group.

   -

Exclusion Criteria:

1. Patients informed but refuse to participate in;
2. Patients with HPA antibodies quitting therapy or breaking off cooperation during research;
3. Patients with many referrals and the time of platelet transfusion can not be confirmed;
4. Patient without platelet transfusion;
5. Patient with termination of treatment whatever active or passive. -
MRD Application in Colorectal Cancer Patients

We first collect tumor tissue and adjacent tissue to peform the WES sequencing, then collect blood after postoperative surgery 1, 3. 6, 9, 12, 18, 24 month to detect ctDNA.

ctDNA is obtained from plasma rather than serum, as the latter contains more DNA released from immune cells during clotting. Blood should be drawn into a K2EDTA or cell stabilization tube (e.g., Streck cfDNA collection tube). Plasma isolation should be performed as soon as possible, no later than 24 hours, using K2EDTA (preferably within 4-6 hours) and, if using cell stabilization tubes, within 2-7 days, temporarily stored at 4°C.

Sample disposal procedure: collect whole anticoagulated blood, gently invert to fully anticoagulate, plasma fractionation should be performed as soon as possible, no later than 24 hours, temporarily stored at 4°C using K2EDTA (preferably within 4-6 hours), and stored at -80°C for long term. The collected anticoagulant blood is placed in an ice box containing ice packs and transported vertically to a centrifugable laboratory. Centrifuge at 3000 rpm at 4°C for 15 min, take the upper layer, and aliquot 0.5 mL/tube into 1.5 mL centrifuge tubes. Cryopreserved at -80 °C, 1 mL of whole blood yields approximately 0.5 mL of plasma.

Eligibility Criteria:
Inclusion Criteria:

(1) Patients with colorectal tumors, whose clinical symptoms meet the diagnostic criteria of colon cancer in my country, and pathologically diagnosed as colorectal cancer after surgery; (2) patients with stage II-III colorectal cancer; (3) aged 30-80 years; (4) All underwent conventional radiotherapy and chemotherapy after operation; (5) Complete clinical data and follow-up records were available.

Exclusion Criteria:

* (1) Other serious diseases (cardiovascular and cerebrovascular diseases, kidney diseases, etc.) before operation; (2) Combined with multiple primary colorectal cancers; (3) Patients with other malignant tumors within the past 5 years; (4) Combined with digestive tract Obstruction, perforation, bleeding and other indications for emergency surgery.
Sarcopenia in Older Patients in the Acute Hospital Setting

This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.

Modern advances in prevention, medical care, and treatments have resulted in an ever-increasing life expectancy and aging of the population. As a result, it is imperative that health care professionals and policy makers develop strategies and new technologies that enable older people to enjoy their advancing years in good health.

Sarcopenia, an age-related decrease in muscle mass, is a major factor in functional decline and frailty and leads to poor quality of life and increased health care costs in older age groups. Because sarcopenia is known to be exacerbated at the time of acute hospital admission, the development of new technologies for the prevention and diagnosis of sarcopenia will have important ramifications in promoting healthy aging in both the acute care and ambulatory settings.

A pilot interventional self-controlled study will be performed in an internal medicine department (internal medicine ward Het) at the Rambam Health Care Campus in Haifa.

Subjects will be evaluated for the risk of sarcopenia by acceptable screening instruments as well as B-mode portable ultrasound. They will then be treated using a stocking-like Virtual Gait Device (VGD) which will be applied to one randomly-assigned lower limb. The VGD is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility.

Confidentiality will be achieved by applying a unique identifier to each trial subject in accordance with Good Clinical Practice standards.

Eligibility Criteria:
Inclusion Criteria:

* Male and female patients 75 years of age and older.
* Patients admitted with an acute infection (clinically from a respiratory or urinary source).
* Expected length of hospitalization of at least 4 days.
* Patients who are conscious and cognitively able to provide written informed consent as determined by a score of 0 on the 4AT scale

Exclusion Criteria:

* Male and female patients under 75 years of age.
* Expected length of hospitalization of less than 4 days.
* A condition limiting the use of the virtual gate device (VGD) due to factors relating to discomfort or safety, including but not limited to: fracture, amputation, local infection, pain, paralysis of one or both lower limbs, cardiac arrhythmia or cardiac pacemaker.
* Patients who are unable to or do not provide informed consent for participation.
* A score 1 or more on the 4AT scale.
Transcranial Photobiomodulation With Patients With Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* idiopathic PD,
* Hoehn \& Yahr stage I-IV,
* independent gait with or without technical assistance
* stable parkinsonian medication for at least a month before the study star.

Exclusion Criteria:

* comorbidities that affect balance or walking,
* other neurological pathologies besides PD,
* chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.


Eligibility Criteria:
Inclusion Criteria:

* undergoing robotic wedge resection or lobectomy for lung mass(es)

Exclusion Criteria:

* emergency case
* history of opiate abuse
* chronic pain syndrome
* intravenous drug use
* chronic use of oral steroids
* pregnancy
* imprisonment
* body weight lower than 70 kg
* liver failure
* uninsured patients
* non-verbal patients or patients who are unable to rate their pain on a visual analogue pain scale
* history of allergic reaction to any of the drugs used in the study: bupivacaine, liposomal bupivacaine, dexamethasone
Effects of Comprehensive Postoperative Pulmonary Tele-Rehabilitation in Elderly Patients With Resectable Lung Cancer

The purpose of this study is to confirm the effectiveness of a mobile messenger-based home tele-rehabilitation protocol in patients who have undergone lung resection surgery.

By analyzing the difference from the existing postoperative pulmonary rehabilitation, the investigators would like to propose a new pulmonary tele-rehabilitation protocol.


Eligibility Criteria:
Inclusion Criteria:

1. A person who is suspected of lung cancer and is scheduled to undergo a thoracoscopic lung resection surgery.
2. men and women the age ≥65 years.
3. A person who understands the course of the clinical trial and signs the informed consent form.

Exclusion Criteria:

1. Patients whose activity is restricted due to other diseases (e.g. osteoarthritis, spinal disease, cerebral infarction, etc.)
2. Patients who cannot test bioimpedance analysis due to the insertion of artificial pacemakers and defibrillators
3. A person who has difficulty judging himself/herself due to dementia, etc
4. Those enrolled in other clinical trials
5. A person deemed inappropriate to participate in this clinical trial under the judgement of the investigator.
6. A person who cannot use mobile messenger